Skip to main content
main-content

01.08.2011 | Research | Ausgabe 4/2011 Open Access

Critical Care 4/2011

Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke

Zeitschrift:
Critical Care > Ausgabe 4/2011
Autoren:
Nai-Wen Tsai, Tsu-Kung Lin, Wen-Neng Chang, Chung-Ren Jan, Chi-Ren Huang, Shang-Der Chen, Kuei-Yueh Cheng, Yi-Fang Chiang, Hung-Chen Wang, Tzu-Ming Yang, Yu-Jun Lin, Wei-Che Lin, Hsueh-Wen Chang, Lian-Hui Lee, Cheng-Hsien Lu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​cc10303) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.
Authors' contributions
NWT and HCW participated in the design of the study and drafted the manuscript. CRJ, KYC, and YFC carried out the flow cytometry study. TKL, CRH, and SDC participated in the sequence alignment and clinical evaluation of patients. WCL interpreted the neuro-imaging studies. HWC, TMY, and YJL performed the statistical analysis. CHL, LHL and WNC conceived the study, and participated in its design and coordination, and helped draft the manuscript. All authors read and approved the final manuscript.

Abstract

Introduction

Statins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterol-lowering. This study aimed to evaluate the effect of pre-existing statin use on platelet activation markers and clinical outcome in acute ischemic stroke patients.

Methods

This prospective study evaluated 172 patients with acute ischemic stroke divided in two groups: patients with pre-existing statin (n = 43) and without pre-existing statin (66 cases with statins initiated post-stroke and 63 without statin treatment). Platelet activation markers (CD62P and CD63) were measured by flow cytometry at different time points after stroke and analyzed with clinical outcome.

Results

The CD62P and CD63 expressions on platelets were significantly lower in the patients with pre-existing statin use compared to the patients without pre-existing statin use on Day 1 post-stroke (p < 0.05). The CD62P expression was significantly lower in the patients with pre-existing statin use on 90 days after the acute stroke (p < 0.05). Patients with pre-existing statin use had lower incidences of early neurologic deterioration (END) than those without treatment (p < 0.05). Among several baseline clinical variables, admission NIHSS score, history of coronary artery disease, and pre-existing statin use were independent predictions of good clinical outcome at three months.

Conclusions

Pre-existing statin use is associated with decreased platelet activity as well as improved clinical outcome and reduced END in patients with acute ischemic stroke.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2011

Critical Care 4/2011 Zur Ausgabe

Neu im Fachgebiet AINS

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update AINS und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise